PMID- 23220362 OWN - NLM STAT- MEDLINE DCOM- 20130812 LR - 20211021 IS - 1873-507X (Electronic) IS - 0031-9384 (Print) IS - 0031-9384 (Linking) VI - 109 DP - 2013 Jan 17 TI - Caffeine prevents weight gain and cognitive impairment caused by a high-fat diet while elevating hippocampal BDNF. PG - 69-74 LID - S0031-9384(12)00403-9 [pii] LID - 10.1016/j.physbeh.2012.11.008 [doi] AB - Obesity, high-fat diets, and subsequent type 2 diabetes (T2DM) are associated with cognitive impairment. Moreover, T2DM increases the risk of Alzheimer's disease (AD) and leads to abnormal elevation of brain beta-amyloid levels, one of the hallmarks of AD. The psychoactive alkaloid caffeine has been shown to have therapeutic potential in AD but the central impact of caffeine has not been well-studied in the context of a high-fat diet. Here we investigated the impact of caffeine administration on metabolism and cognitive performance, both in control rats and in rats placed on a high-fat diet. The effects of caffeine were significant: caffeine both (i) prevented the weight-gain associated with the high-fat diet and (ii) prevented cognitive impairment. Caffeine did not alter hippocampal metabolism or insulin signaling, likely because the high-fat-fed animals did not develop full-blown diabetes; however, caffeine did prevent or reverse a decrease in hippocampal brain-derived neurotrophic factor (BDNF) seen in high-fat-fed animals. These data confirm that caffeine may serve as a neuroprotective agent against cognitive impairment caused by obesity and/or a high-fat diet. Increased hippocampal BDNF following caffeine administration could explain, at least in part, the effects of caffeine on cognition and metabolism. CI - Copyright (c) 2012 Elsevier Inc. All rights reserved. FAU - Moy, Gregory A AU - Moy GA AD - University at Albany, NY 12222, USA. FAU - McNay, Ewan C AU - McNay EC LA - eng GR - R01 DK077106/DK/NIDDK NIH HHS/United States PT - Journal Article DEP - 20121206 PL - United States TA - Physiol Behav JT - Physiology & behavior JID - 0151504 RN - 0 (Blood Glucose) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Central Nervous System Stimulants) RN - 0 (Glucose Transporter Type 4) RN - 0 (Insulin) RN - 0 (Slc2a4 protein, mouse) RN - 3G6A5W338E (Caffeine) RN - EC 2.7.11.1 (Oncogene Protein v-akt) SB - IM MH - Analysis of Variance MH - Animals MH - Blood Glucose/drug effects MH - Brain-Derived Neurotrophic Factor/*metabolism MH - Caffeine/*therapeutic use MH - Central Nervous System Stimulants/*therapeutic use MH - Cognition Disorders/etiology/*prevention & control MH - Diet, High-Fat/*adverse effects MH - Disease Models, Animal MH - Enzyme-Linked Immunosorbent Assay MH - Exploratory Behavior/drug effects MH - Glucose Transporter Type 4/metabolism MH - Hippocampus/drug effects/*metabolism MH - Insulin/blood MH - Male MH - Microdialysis MH - Oncogene Protein v-akt/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Time Factors MH - Weight Gain/*drug effects PMC - PMC3586379 MID - NIHMS431796 EDAT- 2012/12/12 06:00 MHDA- 2013/08/13 06:00 PMCR- 2014/01/17 CRDT- 2012/12/11 06:00 PHST- 2012/06/25 00:00 [received] PHST- 2012/11/14 00:00 [revised] PHST- 2012/11/28 00:00 [accepted] PHST- 2012/12/11 06:00 [entrez] PHST- 2012/12/12 06:00 [pubmed] PHST- 2013/08/13 06:00 [medline] PHST- 2014/01/17 00:00 [pmc-release] AID - S0031-9384(12)00403-9 [pii] AID - 10.1016/j.physbeh.2012.11.008 [doi] PST - ppublish SO - Physiol Behav. 2013 Jan 17;109:69-74. doi: 10.1016/j.physbeh.2012.11.008. Epub 2012 Dec 6.